ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.

More documents

Recommendations

Info

UNCE 204013. References Stulc T., Sedo A.: Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 88(2): 125-3, 2010 40. NONCLASSICAL CD16 + PERIPHERAL BLOOD MONOCYTES EXPRESS CD11C WITH HIGH INTENSITY IN EARLY RHEUMATOID ARTHRITIS Olga Kryštůfková, Heřman Mann, Hana Hulejová, Ladislav Šenolt, Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic and Dept. of Rheumatology, 1 st Faculty of Medicine, Charles University, Prague, Czech Republic, krys@revma.cz Three populations of human monocytes have been described based on the relative expression of surface markers CD14 and CD16, as classical (CM; CD14 + CD16 - ), nonclassical (NCM; CD14 dim CD16 ++ ) and intermediate (IM; CD14 + CD16 +/++ ) [1]. NCM are potent antigen presenting cells and producers of proinflammatory cytokines, with high migratory ability and are involved in Fc mediated killing. They were enriched in peripheral blood (PB) of patients with rheumatoid arthritis (RA) and correlated with disease activity and titers of rheumatoid factor [2-5]. Response to therapy with methotrexate (MTX) was associated with reduction of CD16 expression [4,5]. Higher expression of CD16 on RA synovial fluid monocytes compared to PB and in RA synovium was reported. CD11c expressed by human monocytes, is involved in clearance of immune complexes, plays a role in antigen presentation and in production of proinflammatory cytokines. Higher expression of CD11c on mononuclear blood cells (PBMC) in patients with RA, expansion of CD11c positive inflammatory macrophages in RA synovium and a predictive role of higher CD11c mRNA expression for response to TNFα blocking treatment in RA were shown [6-8]. The aim of this study was to evaluate the expression of CD11c on monocyte subpopulations in patients with early rheumatoid arthritis (ERA) and to compare them to patients with osteoarthritis (OA). We also studied changes of CD11c expression after three months of treatment. Thirty one patients with Early Rheumatoid Arthritis (ERA) and 9 gender and age-matched patients with osteoarthritis (OA) were included. Patients in the ERA cohort had symptom duration < 6 months and either fulfilled the 2010 ACR/EULAR classification criteria for RA or had undifferentiated inflammatory arthritis. Serum CRP and anti-CCP autoantibody levels and rheumatoid factor positivity were recorded. Disease activity was assessed using DAS28. Monocytes were selected using a sequential gating approach by exclusion of doublets (high FSc Area plotted in versus FSc Lin), granulocytes (SSc high granular events), CD45 - events and HLADR - /CD3 + /CD19 + lymphocytes. Their subpopulations were defined based on the positivity of CD14 and CD16 according to IUIS nomenclature [1]. Classical monocytes were defined as CD14 + CD16 - and non-classical as CD14 dim CD16 ++ . With use of Analytical Cytometry VII 59
isotype controls and FMO for CD14 and CD16; two intermediate (IM) populations were evaluated separately as CD14 + CD16 + and CD14 + CD16 ++ . In these monocyte populations, intensity of CD11c expression was analysed as the median intensity of fluorescence (MFI). ERA patients had lower proportions of intermediate monocyte subsets (IM-CD16 + p=0.02 and IM-CD16 ++ p=0.15) and more classical monocytes (p=0.009) compared to OA. The presence of thyroiditis (n=3) was associated with higher proportion of non-classical and intermediate monocytes (p=0.01 and p=0.04). Majority of monocytes expressed CD11c (median 98.2%). NC monocytes had highest expression of CD11c (MFI 558.9 ± 117) compared to CM (MFI 331.7 ± 93.13; p
Page 1 and 2: ABSTRACTS - ORAL PRESENTATIONS 14.
Page 3 and 4: and (iii) siRNA-mediated knockdown
Page 5 and 6: 25. PROFILING OF CHILDHOOD ACUTE LE
Page 7 and 8: more dominantly than Th1 and CD4 ce
Page 9 and 10: 29. INFLUENCE OF THE LEVEL OF CD133
Page 11 and 12: 36. B-CELL IMMUNOPHENOTYPING OF LAR
Page 13: possible mechanism behind risk alle
Page 17 and 18: NEP developmental stages were disti
Page 19 and 20: 50. THE PROGRESSION OF HIV INFECTIO
Page 21 and 22: 52. PRŮKAZ REGULAČNÍCH T LYMFOCY
Page 23 and 24: values when analysing paediatric ly
Page 25 and 26: 42,0) vs. 1,5 (0,0-28), p
Page 27 and 28: for application of proton therapy,
Page 29 and 30: effects will be also characterized
Page 31 and 32: Although multiple signalling pathwa
Page 33 and 34: an ability to recreate the tumour f
Page 35 and 36: incubated with non-filtered superna
Page 37 and 38: approaches how to detect and isolat
Page 39 and 40: progress in development of automate
Page 41 and 42: tissues is characteristic for a num
Page 43 and 44: kappaB. Beside that, we found OANO
Page 45 and 46: therapy in patients (Calderwood et
Page 47 and 48: difference in the effect caused eit
Page 49 and 50: 4 CIC bioGUNE Technology Park of Bi
Page 51 and 52: P8. PROADIFEN (SKF-525A) ATTENUATES
Page 53 and 54: models. As manifested by compromise
Page 55 and 56: P11. NEW BIOACTIVE AND FLUORESCENT
Page 57 and 58: Acetylation of histones, along with
Page 59 and 60: stimulated cells. The physiological
Page 61 and 62: h induced very minor manifestations
Page 63 and 64: chemotherapeutic drug LA-12. These
Page 65 and 66:
aberrant expression, localization a
Page 67 and 68:
P21. ASSESSMENT OF MITOCHONDRIAL FU
Page 69 and 70:
P23. PTEROSTILBENE: COMPARISON OF A
Page 71 and 72:
Fam123b. Amer1 has been shown very
Page 73 and 74:
In summary, we described different
Page 75 and 76:
this process. Combined treatment wi
Page 77 and 78:
Homolog 1) gene; previously identif
Page 79 and 80:
egulate expression of different gen
Page 81 and 82:
was harmful neither alone nor in co
Page 83 and 84:
P34. PHARMACOLOGICAL INHIBITION OF
Page 85 and 86:
novel chemotherapeutics with specif
Page 87 and 88:
P38. EVIDENCE OF ABNORMAL PERIPHERA
Page 89 and 90:
acid to 5-lipoxygenase. Similarly t
Page 91 and 92:
P41. WHY CAN WE SEE DIFFERENT RADIO
Page 93 and 94:
P42. ELUCIDATION OF CROSSTALK BETWE
Page 95 and 96:
P44. INSTRUMENT SETTINGS FOR EUROFL
Page 97 and 98:
e used to cultivate endothelial cel
Page 99 and 100:
concentrations 0.15, 0.2, 0.3 and 0
Page 101 and 102:
P49. NEW ANALOGS OF RHODAMINE Jiři
Page 103 and 104:
P51. FLUORESCENCE-LABELED FERROMAGN
Page 105 and 106:
could be achieved via the activatio
Page 107 and 108:
28. Pp. 1565-1570. 2008. Dearden C:
Page 109 and 110:
cells (SFC) using IFN-γ Elispot in
Page 111 and 112:
FACSCantoII flow cytometer (Becton
Page 113 and 114:
P59. EARLY DIAGNOSTICS OF CARTILAGE
Page 115 and 116:
cross-reacting group (CREG) and sha
Page 117 and 118:
the frequency of autoimmune disease
Page 119 and 120:
non-covalent bonds. For a solution
Page 121 and 122:
P65. OVULATION STIMULATION PROTOCOL
Page 123 and 124:
Acknowledgements This work was supp
Page 125 and 126:
P68. SUBPOPULATIONS OF B LYMPHOCYTE
Page 127 and 128:
triggers a process of normal blood
Page 129 and 130:
3 Department of Internal Medicine -
Page 131 and 132:
P73. THE V-ATPASE-INHIBITOR BAFILOM
Page 133 and 134:
P75. 5-FLUOROURACIL-SELECTED TUMOUR
Page 135 and 136:
We conclude that decrease in the po
Page 137 and 138:
Acknowledgements This work was supp
Page 139 and 140:
P79. NEW TYPE OF PHOTOSENSITIZER IS
Page 141 and 142:
LD11015, from GAČR 13-29358S, and
Page 143 and 144:
P83. DIFFERENTIATION OF NEURAL CRES
Page 145 and 146:
given cell type are missing and the
Page 147 and 148:
and HistoPARK (CZ.1.07/2.3.00/20.01
Page 149 and 150:
Our results show that both p38α +/
Page 151 and 152:
P90. TOLL-LIKE RECEPTOR 2 TRACKS TH
Page 153 and 154:
for chemokines in attracting “inf
Page 155:
in immune organs (Bursa of Fabricii
show all

ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.